Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has earned a consensus recommendation of “Buy” from the twenty-three analysts that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $131.63.
A number of research analysts have commented on ICPT shares. ValuEngine raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $73.00 price objective on the stock in a report on Monday, July 15th. BidaskClub raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Royal Bank of Canada set a $135.00 price objective on Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Friday, September 6th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $86.00 price objective on shares of Intercept Pharmaceuticals in a report on Monday, August 12th.
NASDAQ ICPT traded up $0.83 on Friday, reaching $68.90. The stock had a trading volume of 816,252 shares, compared to its average volume of 427,716. The company has a debt-to-equity ratio of 3.11, a current ratio of 6.54 and a quick ratio of 6.54. The firm has a fifty day moving average of $63.96 and a two-hundred day moving average of $84.05. Intercept Pharmaceuticals has a 1-year low of $58.21 and a 1-year high of $133.74. The company has a market cap of $2.26 billion, a P/E ratio of -6.34 and a beta of 1.21.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($2.28) EPS for the quarter, beating analysts’ consensus estimates of ($2.51) by $0.23. Intercept Pharmaceuticals had a negative return on equity of 534.42% and a negative net margin of 143.57%. The firm had revenue of $66.30 million for the quarter, compared to analyst estimates of $58.78 million. During the same period in the prior year, the firm posted ($2.58) EPS. The company’s revenue for the quarter was up 52.2% on a year-over-year basis. Research analysts predict that Intercept Pharmaceuticals will post -9.99 EPS for the current fiscal year.
In related news, insider Lisa Bright sold 595 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $78.66, for a total transaction of $46,802.70. Following the completion of the sale, the insider now directly owns 20,452 shares in the company, valued at approximately $1,608,754.32. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Srinivas Akkaraju acquired 5,207 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were acquired at an average price of $60.32 per share, with a total value of $314,086.24. Following the completion of the transaction, the director now owns 21,526 shares in the company, valued at $1,298,448.32. The disclosure for this purchase can be found here. 5.00% of the stock is owned by corporate insiders.
Several hedge funds have recently made changes to their positions in ICPT. Water Island Capital LLC bought a new position in Intercept Pharmaceuticals in the second quarter valued at about $481,000. Atria Investments LLC bought a new position in Intercept Pharmaceuticals in the second quarter valued at about $548,000. Perceptive Advisors LLC bought a new position in Intercept Pharmaceuticals in the second quarter valued at about $7,766,000. Nuveen Asset Management LLC raised its position in Intercept Pharmaceuticals by 1,546.6% in the second quarter. Nuveen Asset Management LLC now owns 120,891 shares of the biopharmaceutical company’s stock valued at $9,619,000 after purchasing an additional 113,549 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in Intercept Pharmaceuticals by 63.5% in the second quarter. UBS Asset Management Americas Inc. now owns 157,041 shares of the biopharmaceutical company’s stock valued at $12,496,000 after purchasing an additional 61,017 shares during the last quarter. Institutional investors and hedge funds own 80.97% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
See Also: Fundamental Analysis
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.